“…Mucocutaneous (4.84%) manifestations were most common, followed by musculoskeletal (1.32%), ocular (0.88%), hepatobiliary (0.44%), and vascular (0.44) manifestations. These findings draw our attention to the myriad ramifications of IBD, which are not limited to systemic effects alone, as is emerging in other studies [ 7 ]. Clinicians should carefully assess EIMs at diagnosis and through the course of the patient’s journey to ensure optimal outcomes.…”